Publications

Publications of specific relevance to Predictive
in vitro Models
2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports,
Springer Science and Business Media Llc vol. 75 (3), 753-753.
17-05-2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports,
Springer Science and Business Media Llc vol. 75 (3), 570-584.
03-04-20232021
Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacyGonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM et al.
Acta Biomaterialia,
Elsevier Bv vol. 134, 593-604.
01-10-20212019
Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancerStella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G
Scientific Reports,
Springer Science and Business Media Llc vol. 9 (1)
06-09-2019
ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY In
Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology,
World Scientific (Europe) 323-345.
17-07-2019
Improved replication and selectivity of oncolytic AdΔΔ and Ad-3Δ-A20T promotes targeting to distant lesions in preclinical pancreatic cancer modelsHallden G
01-01-20192018
Advances in oncolytic adenovirus therapy for pancreatic cancerNattress CB, Halldén G
Cancer Letters,
Elsevier Bv vol. 434, 56-69.
01-10-2018
Designer Oncolytic Adenovirus: Coming of AgeBaker A, Aguirre-Hernández C, Halldén G, Parker A
Cancers,
Mdpi Ag vol. 10 (6), 201-201.
14-06-2018
The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer CellsMan YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G
Molecular Cancer Therapeutics,
American Association For Cancer Research (Aacr) vol. 17 (2), 575-587.
01-02-2018
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagyAguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu Y-J, Halldén G
Oncogenesis,
Springer Science and Business Media Llc vol. 7 (1)
24-01-20182017
Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenovirusesHallden G
01-01-2017
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagyAguirre-Hernandez C, Maya-Pineda H, Millan JS, Man YKS, Lu YJ, Hallden G
01-01-2017
The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6-integrins efficiently eliminates pancreatic cancer cellsMan YKS, Davies JA, Coughlan L, Pantelidou C, Marshall JF, Parker AL, Hallden G
01-01-20172016
Oncolytic adenovirus-mediated therapy for prostate cancerHallden G, Sweeney K
Oncolytic Virotherapy,
Informa Uk Limited vol. Volume 5, 45-57.
01-07-2016
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Pantelidou C, Cherubini G, Lemoine NR, Halldén G
Oncotarget,
Impact Journals, Llc vol. 7 (13), 15703-15724.
10-02-2016
The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells.Hernandez CA, Hallden G
01-01-2016
The adenoviral AdΔΔ mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells.Aguirre-Hernandez C, Millan JS, Hallden G
01-01-2016
Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damagePantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H, Hallden G
International Journal of Molecular Medicine vol. 38, S58-S58.
01-01-20162015
An oncolytic adenovirus (AdΔ19K) sensitizes pancreatic cancer cells to cytotoxic drugs by promoting DNA-damage and aberrant mitosis through inactivation of checkpoint mediators.Pantelidou C, Hallden G
01-01-20152014
Abstract 713: Utilizing a potent and selective nonreplicating adenoviral mutant (Ad5-TV-CU), with gene expression controlled by androgen receptor-dependent activation domains in the TMPRSS2 gene, as a novel prodrug-converting enzyme therapy for prostate cancerMercer EJ, Imrali A, Sharpe K, Hallden G, Lu Y-J
01-10-2014
18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY In
Icp Textbooks in Biomolecular Sciences,
Imperial College Press 307-329.
14-01-2014
Oncolysis is greatly enhanced by retargeting of replication-selective adenoviral mutants to avβ6-integrin expressing cancers and in combination with cytotoxic drugsMan YKS, Coughlan L, Pantelidou C, Hallden G
01-01-2014
Adenoviruses deleted in the anti-apoptotic E1B19K-gene synergise with DNA-damaging drugs through attenuation of DNA-damage repair responses and checkpoint activation in pancreatic cancer cellsPantelidou C, Lemoine N, Hallden G
01-01-20142013
Ionizing radiation enhances dl922–947-mediated cell death of anaplastic thyroid carcinoma cellsPassaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G et al.
Endocrine-Related Cancer,
Bioscientifica vol. 20 (5), 633-647.
01-10-20132012
Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-RegionMiranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G
Plos One,
Public Library of Science (Plos) vol. 7 (10), e46617-e46617.
03-10-2012
Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer ModelsAdam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR et al.
Human Gene Therapy,
Mary Ann Liebert Inc vol. 23 (9), 1003-1015.
01-09-2012
Oncolytic virotherapy with modified adenoviruses and novel therapeutic targetsHalldén G, Portella G
Expert Opinion On Therapeutic Targets,
Informa Uk Limited vol. 16 (10), 945-958.
13-08-2012
Inhibition of Autophagy Enhances the Effects of E1A-Defective Oncolytic Adenovirus dl922–947 Against Glioma Cells In Vitro and In VivoBotta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F et al.
Human Gene Therapy,
Mary Ann Liebert Inc vol. 23 (6), 623-634.
01-06-2012
Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cellsSweeney KG, Cheong SC, Lemoine NR, Hallden G
Cancer Research,
American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2712-2712.
15-04-2012
Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cellsMaya-Pineda HR, Miranda-Rota E, Lemoine NR, Halldén G
Cancer Research,
American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2713-2713.
15-04-20122011
The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer modelsCherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G
Gene Therapy,
Springer Science and Business Media Llc vol. 18 (12), 1157-1165.
06-10-2011
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabineBhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G
Cancer Gene Ther vol. 18 (10), 734-743.
01-10-2011
Adenoviral Gene Expression and Replication in Human Tumor Explant ModelsHalldén G
,
Humana Press, 65-78.
23-08-2011
Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K genePantelidou C, Cherubini G, Lemoine NR, Hallden G
Human Gene Therapy vol. 22 (10), A119-A120.
01-01-2011
A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cellsSweeney K, Cheong SC, Lemoine N, Hallden G
Human Gene Therapy vol. 22 (10), A122-A122.
01-01-2011
Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cellsMaya-Pineda H, Miranda E, Lemoine N, Hallden G
Human Gene Therapy vol. 22 (10), A104-A104.
01-01-20112010
Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancerIngemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA
Oncogene vol. 29 (45), 6051-6063.
01-11-2010
Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor XenograftsRadhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Hallden G
Hum Gene Ther vol. 21 (10), 1311-1325.
01-10-2010
Adenovirus-based therapy for prostate cancerEkblad M, Hallden G
Curr Opin Mol Ther vol. 12 (4), 421-431.
01-08-2010
Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic CancersOberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Hallden G
Clin Cancer Res vol. 16 (2), 541-553.
15-01-2010
A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cellsSweeney K, Cheong SC, Lemoine N, Hallden G
01-01-2010
Development of an oncolytic adenovirus expressing the prodrug-converting enzyme CD/UPRT (AdΔΔCU)Ekblad M, Oberg D, Lemoine N, Hallden G
01-01-2010
Investigating a new potent and selective oncolytic adenovirus (AdΔΔ) in combination with chemotherapyCherubini G, Kalllin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N, Hallden G
01-01-20102009
P2Y5 is a G alpha(i), G alpha(12/13) G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesionLee M, Choi S, Hallden G, Yo SJ, Schichnes D, Aponte GW
Am J Physiol-Gastr L vol. 297 (4), G641-G654.
01-10-2009
Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivoLeitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Hallden G
Clin Cancer Res vol. 15 (5), 1730-1740.
01-03-2009
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeuticsHallden G
Journal of Buon vol. 14, S61-S67.
01-01-2009
Critical Role for p21 and p27 in Efficacy of Oncolytic Adenovirus dl922-947 in Ovarian CancerFlak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA
01-01-2009
Prostate Cancer Targeting by Replication-Selective Adenoviral Mutants: Combination Treatments with Phytochemical DrugsAdam V, Oberg D, Lemoine N, Hallden G
01-01-20092008
Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947Libertini S, Iacuzzo I, Perruolo G, Scala S, Ieranò C, Franco R, Hallden G, Portella G
Clinical Cancer Research,
American Association For Cancer Research (Aacr) vol. 14 (20), 6505-6514.
15-10-2008
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirusBazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Hallden G, Mautner V et al.
Hum Gene Ther vol. 19 (9), 873-886.
01-09-2008
Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic AdenovirusBazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V, Shen J et al.
Human Gene Therapy,
Mary Ann Liebert Inc (ja), 08101509322-08101509322.
27-06-2008
Inhibition of late-stage prostate cancer using adenoviral mutants: Expression of an androgen receptor co-repressor and AR-siRNACheong SC, Oberg D, Nick L, Hallden G
01-01-2008
Prostate cancer targeting by replication-selective adenoviral mutants: combination treatments with phytochemical drugsAdam V, Lemoine N, Hallden G
01-01-2008
Prostate cancer targeting by replication-selective adenoviral mutants: Combination treatments with phytochemical drugsAdam VS, Lemoine N, Hallden G
01-01-2008
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models Cancer Gene Ther vol. 15 (1), 40-50.
01-01-2008
Host cell factors in ovarian cancer influencing efficacy of oncolytic adenovirus dl922-947Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA
01-01-20082007
Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating AdenovirusesGaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M
Cancer Research,
American Association For Cancer Research (Aacr) vol. 67 (15), 7284-7294.
01-08-2007
GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cellsChoi S, Lee M, Shiu AL, Yo SJ, Halldén G, Aponte GW
American Journal of Physiology-Gastrointestinal and Liver Physiology,
American Physiological Society vol. 292 (5), G1366-G1375.
01-05-2007
548: Synergistic Enhancement of Cell Death by Combination Therapy with Adenovirus and ChemotherapyRadhakrishnan S, Hallden GK, Chinegwundoh F, Lemoine N
01-04-2007
Lysis of dysplastic but not normal organotypical oral epithelium with conditionally replicating adenovirusesGaballah K, Partridge M, Hills A, Curiel D, Hallden G, Harrison P
01-01-2007
Synergistic enhancement of prostate cancer cell death by combination therapy of adenovirus and chemotherapyRadhakrishnan S, Hallden G, Chinegwundoh F, Lemoine N
01-01-2007
Inhibition of androgen receptor signaling pathways in prostate cancer cells by adenoviral vectors expressing Hey1Cheong SC, Lemoine N, Hallden G
01-01-20072006
Oncolytic virotherapy for nasopharyngeal cancer Clinical Otolaryngology,
Wiley vol. 31 (6), 582-583.
01-12-2006
Synergistic interactions between adenovirus and chemotherapy in pancreatic cancer cell lines: Effects of chemotherapy on expression of coxsackie-adenovirus receptor (CAR) and infectability by adenovirusBhattacharyya M, Hallden G, Francis J, Lemoine NR
01-01-20062005
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus Gene Ther vol. 12 (17), 1333-1346.
01-09-2005
Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors Cancer Res vol. 65 (4), 1523-1531.
15-02-2005
Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activityLee M, Hadi M, Hallden G, Aponte GW
J Biol Chem vol. 280 (1), 125-136.
07-01-2005
A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses Clin Cancer Res vol. 11 (1), 351-360.
01-01-20052004
Interleukin-1 beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite Int J Oncol vol. 25 (1), 173-178.
01-07-2004
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency Mol Ther vol. 9 (6), 786-803.
01-06-2004
Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture 01-01-2004
VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours 01-01-2004
Combination of a second generation genetically modified herpes simplex virus 1 (HSV 1) with paclitaxel in the treatment of breast cancer in vitroHu J, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes R
01-01-2004
Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity 01-01-2004
The gene expression and function of adenoviral E3-genes in murine tumour cell lines 01-01-2004
Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro.Hu JC, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes C
01-01-20042003
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models Nat Biotechnol vol. 21 (11), 1328-1335.
01-11-2003
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy Mol Ther vol. 8 (3), 412-424.
01-09-2003
Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity 01-01-2003
In vitro screening of murine carcinoma cell lines for testing of replication-competent oncolytic adenovirusesHill RJ, Hallden GK, Lemoine NR, Kirn DH
01-01-2003
Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor 01-01-20032002
The emerging fields of suicide gene therapy and virotherapyKirn D, Niculescu-Duvaz I, Hallden G, Springer CJ
Trends Mol Med vol. 8 (4), S68-S73.
01-01-20021994
Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cellsHallden G, Holehouse EL, Dong X, Aponte GW
American Journal of Physiology-Gastrointestinal and Liver Physiology,
American Physiological Society vol. 267 (4), G730-G743.
01-10-19941989
Trophic effect of amniotic fluid on cultured fetal gastric mucosal cellsMulvihill SJ, Hallden G, Debas HT
Journal of Surgical Research,
Elsevier Bv vol. 46 (4), 327-329.
01-04-1989
Purification of the pancreatic cholecystokinin receptorSzecowka J, Hallden G, Goldfine ID, Williams JA
Regulatory Peptides,
Elsevier Bv vol. 24 (3), 215-224.
01-03-1989
Replication-Selective Oncolytic AdenovirusesHalldén G, Thorne SH, Yang J, Kirn DH
,
Humana Press, 71-90.